National Institute for Health Care Research
NHS patients to access Theramex’s endometriosis pill following NICE recommendation
The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment
NICE recommends Theramex’s Eladynos to treat bone disease after menopause
Osteoporosis, which particularly impacts older women after menopause, currently affects 3.8 million people in the UK
Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
More than ten million adults in the US alone over the age of 50 are estimated to have the condition
Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis
In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year
UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe
First new drug for the disease in the EU since 2010
Amgen and UCB’s Evenity finally approved, but with label warnings
Drug unlikely to match Prolia's revenues
Evenity back on track with FDA panel blessing in osteoporosis
US drugs regulator first rejected the drug due to cardiovascular concerns
Cuttsy+Cuttsy launch their latest patient e-book
On the eve of ‘World Osteoporosis Day’ (worldosteoporosisday.org), Cuttsy+Cuttsy are proud to launch their latest e-book ‘Osteoporosis…in plain English’.
FDA rejects Amgen’s osteoporosis hope romosozumab
Its partner UCB plans to submit the medicine for European approval later this year
Amgen’s Kyprolis scarred by head-to-head duel with Velcade
Failed to show superior progression-free survival in first-line treatment trials
Merck decision to drop odanacatib lifts UCB/Amgen
Pulls plug on osteoporosis candidate after studies show high risk of stroke